SLC5A2 and urinary tract infection: Not least, SGLT2 inhibitors are frequently co-administered with other classes of drugs in the complex treatment regimens of diabetic patients with cardiovascular and renal disease, and the drug interactions could increase the risk of urinary tract infections.